Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on: October 11,2023 261

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on:October 11,2023 261

Drug development in stem cell-derived liver organoid models

To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outli

Updated on: November 01,2023 5

Drug development in stem cell-derived liver organoid models

To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outli

Updated on:November 01,2023 5

Study finds carcinogen exposure makes cancer cells more susceptible to immune attack

by Liz Murphy,Massachusetts General HospitalCarcinogen-exposed cancer cells transform that nature of tumor-infiltrating macrophages from immunosuppressive (left) to immune activating agents (rig

Updated on: October 31,2023 2

Study finds carcinogen exposure makes cancer cells more susceptible to immune attack

by Liz Murphy,Massachusetts General HospitalCarcinogen-exposed cancer cells transform that nature of tumor-infiltrating macrophages from immunosuppressive (left) to immune activating agents (rig

Updated on:October 31,2023 2

NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL

September 30, 2023Ryan Scotthe novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloid

Updated on: October 24,2023 267

NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL

September 30, 2023Ryan Scotthe novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloid

Updated on:October 24,2023 267

Why does a leukemic mutation not always lead to leukemia? A new clue from a mouse study

byKeck School of Medicine of USCCredit: Pixabay/CC0 Public DomainWhy do some people with a genetic mutation associated with leukemia remain healthy, while others with the same mutation develop t

Updated on: January 08,2024 8

Why does a leukemic mutation not always lead to leukemia? A new clue from a mouse study

byKeck School of Medicine of USCCredit: Pixabay/CC0 Public DomainWhy do some people with a genetic mutation associated with leukemia remain healthy, while others with the same mutation develop t

Updated on:January 08,2024 8

Pharmacotyping of childhood leukemia provides a blueprint for 'true precision medicine'

bySt. Jude Children's Research HospitalWenjian Yang, Shawn Lee, MBBS, and Jun J. Yang, PhD, recently published a comprehensive study pharmacotyping childhood leukemia. Credit: St. Jude Child

Updated on: December 21,2023 10

Pharmacotyping of childhood leukemia provides a blueprint for 'true precision medicine'

bySt. Jude Children's Research HospitalWenjian Yang, Shawn Lee, MBBS, and Jun J. Yang, PhD, recently published a comprehensive study pharmacotyping childhood leukemia. Credit: St. Jude Child

Updated on:December 21,2023 10

Blood Thinners: What You Should Know

Blood Thinners: What You Should KnowByAngela Ryan Lee, MDPublished on January 24, 2022Medically reviewed byAnisha Shah, MDBlood thinners are medications used to treat and

Updated on: March 17,2024 0

Blood Thinners: What You Should Know

Blood Thinners: What You Should KnowByAngela Ryan Lee, MDPublished on January 24, 2022Medically reviewed byAnisha Shah, MDBlood thinners are medications used to treat and

Updated on:March 17,2024 0

IMNN-001 Plus Neoadjuvant Chemotherapy Improves PFS in Advanced Ovarian Cancer

September 28, 2023Chris RyanTreatment with the interleukin-12 gene-mediated immunotherapy IMNN-001 in combination with neoadjuvant platinum chemotherapy led to an improvement in progression-free survi

Updated on: October 10,2023 280

IMNN-001 Plus Neoadjuvant Chemotherapy Improves PFS in Advanced Ovarian Cancer

September 28, 2023Chris RyanTreatment with the interleukin-12 gene-mediated immunotherapy IMNN-001 in combination with neoadjuvant platinum chemotherapy led to an improvement in progression-free survi

Updated on:October 10,2023 280

Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors

September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo

Updated on: October 12,2023 22

Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors

September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo

Updated on:October 12,2023 22

Why start mammograms at 40? Doctor explains new advice

by Samantha Laine Perfas,Harvard UniversityCredit: Unsplash/CC0 Public DomainWomen should start getting regular mammograms at the age of 40, according toa new recommendationbeing dra

Updated on: January 08,2024 10

Why start mammograms at 40? Doctor explains new advice

by Samantha Laine Perfas,Harvard UniversityCredit: Unsplash/CC0 Public DomainWomen should start getting regular mammograms at the age of 40, according toa new recommendationbeing dra

Updated on:January 08,2024 10

Researchers surprised by high levels of alcohol consumption among cancer survivors

by National Comprehensive Cancer NetworkCredit: CC0 Public DomainNew research in the January 2020 issue ofJNCCN—Journal of the National Comprehensive Cancer Networkuses data from the Natio

Updated on: December 20,2023 22

Researchers surprised by high levels of alcohol consumption among cancer survivors

by National Comprehensive Cancer NetworkCredit: CC0 Public DomainNew research in the January 2020 issue ofJNCCN—Journal of the National Comprehensive Cancer Networkuses data from the Natio

Updated on:December 20,2023 22

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MD Prithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal t

Updated on: October 10,2023 296

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MD Prithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal t

Updated on:October 10,2023 296